Gastrointestinal Cancer News

Individuals at risk for Lynch syndrome are not often being advised to undergo genetic testing and may not be getting colonoscopies at intervals recommended by current guidelines, according to study results.

In a prospective cohort study, patients with hepatocellular carcinoma who underwent anatomic resection had decreased risk for recurrence compared with patients who did not, according to data published in the Journal of Hepatology.

The decision to exclude patients with gastrointestinal cancers from clinical trials simply because they had a prior malignancy is unjustified, according to results of a retrospective observational study.

High epiregulin and amphiregulin expression levels appeared to serve as a predictive biomarker for PFS benefit from panitumumab therapy in patients with RAS wild-type advanced colorectal cancer, according to a retrospective analysis of a randomized clinical trial.

As the prevalence of colorectal cancer rises “slowly and steadily” among patients under the age of 50 years, clinicians have three major opportunities to reduce the disease in this population, according to Matthew Kalady, MD, a colorectal surgeon at Cleveland Clinic.

AliveAndKickn has announced the launch of the HEROIC Registry, a genetic database for people with Lynch Syndrome to share data and further research, according to a press release.

The turmoil of December and early January has died down, and I have had time to think about the upcoming year, which seems to offer the possibility of being a year that could present some substantial hazards.

The risk for cardiovascular disease appeared greater among adult survivors of certain cancer subtypes, including multiple myeloma, lung cancer, non-Hodgkin’s lymphoma and breast cancer, according to the results of a retrospective study.

In a U.S. Veteran population, a majority of patients with hepatocellular carcinoma had undetected cirrhosis at the time carcinoma was diagnosed. These patients were also more likely to have advanced stage HCC.

Unprovoked venous thromboembolism appeared associated with a consistently high risk for subsequent cancer diagnosis, according to results of a population-based cohort study.